Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Shareholder vote
confidence 92%
filed 2026-06-23
EX-99.1
The exhibit discloses voting results from Metalla's annual general meeting held June 23, 2026, including detailed vote tallies for seven director nominees (all approved with >95% support), approval of KPMG LLP as auditor, and approval of the share compensation plan. This is a classic shareholder_vote_results disclosure. The concurrent announcement of Sandeep Singh's market purchase of 150,000 shares and matching RSU award is secondary context to his election as director and is not a separate material event requiring distinct classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-23
Item 7.01
The filing discloses a proposed acquisition of Vacuumschmelze GmbH & Co. KG and related group companies from Ara Partners, with an investor presentation furnished as Exhibit 99.1. This constitutes material M&A activity under Item 7.01 (Regulation FD Disclosure), which is commonly used to furnish investor materials related to significant transactions. The acquisition of a named foreign entity represents a material acquisition event that would affect investor assessment of the registrant.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-23
Item 5.07
This is a clear disclosure of shareholder vote results from the June 17, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes for three proposals: election of a Class II director (Matthew C. Winger), ratification of the independent auditor (Stephano Slack LLC), and advisory approval of named executive officer compensation. All three proposals were approved. This is a standard Item 5.07 disclosure of shareholder meeting results, which is material to investors as it reflects governance decisions and shareholder approval of key matters.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-23
Item 5.02
Mr. Ian Wendler, an Independent Director and Audit Committee member, is retiring from the Board effective July 31, 2026. The filing explicitly cites Item 5.02(b), which governs director departures. While the retirement is amicable and not due to disagreement, the loss of an independent director with audit committee responsibilities is material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-23
EX-99.1
GFL announced the pricing of US$750 million in aggregate principal amount of senior notes due 2031 with a 5.625% coupon. This is a material creation of a direct financial obligation through debt issuance. The proceeds are earmarked to repay revolving credit facility amounts and fund the previously announced SECURE Waste Infrastructure Corp. acquisition, making this a significant capital-raising event that would affect a reasonable investor's assessment of the company's financial structure and leverage.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-23
Item 8.01
FirstCash announced a recommended cash acquisition of Ramsdens Holdings PLC for approximately £206 million ($273 million USD) through its subsidiary Chess Bidco Limited, expanding FirstCash's U.K. pawn store presence from approximately 296 to over 470 combined locations. The transaction is subject to shareholder and regulatory approvals with expected completion by end of 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 94%
filed 2026-06-23
Item 1.01
Nuvectis entered into a material definitive license agreement with Haisco Pharmaceutical Group on June 22, 2026, acquiring exclusive ex-China rights to develop, manufacture, and commercialize two clinical-stage drug candidates (NXP100 and NXP200). The transaction involves an upfront payment of $20 million, up to $20 million in initial development milestones, and up to $1.4 billion in contingent payments, representing a material acquisition of intellectual property and development rights that transforms the company's pipeline and strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 8.01
Armata announced receipt of $2.5 million in additional non-dilutive Department of Defense funding for development of AP-SA02, bringing total DoD support to $28.7 million. This is a material operational and strategic event—non-dilutive funding supports Phase 3 readiness of a lead clinical candidate—but does not fit the specific categories of debt issuance, equity dilution, or other named financial/operational types. The funding is operational in nature (supporting clinical development) rather than a discrete financial obligation or capital raise.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-23
EX-99.1
The exhibit announces the appointment of Ms. Qianfei Chang as an independent director, audit committee chairman, and member of two other board committees, effective July 1, 2026. While the disclosure also mentions Mr. Heping Feng's resignation, the principal disclosed action is the appointment of a new director with significant financial and audit expertise to key governance roles. This is material to investors as it affects board composition and oversight functions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-23
Item 7.01
Sunstone Hotel Investors has entered into a definitive agreement to sell the 821-room Hyatt Regency San Francisco to Blackstone Real Estate for $279 million. This is a material disposition of a significant asset representing a substantial portion of the company's real estate portfolio. The transaction is expected to close in late July or early August 2026, and the company has already begun deploying proceeds into share repurchases, demonstrating the materiality of this capital event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 1.01
AMC entered into a securities purchase agreement on June 23, 2026 to sell 95,250,000 shares of Class A common stock at $2.10 per share in a registered direct offering, raising approximately $200 million in gross proceeds for debt redemption and general corporate purposes. This material registered equity issuance will dilute existing shareholders' voting power and ownership percentage.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This Item 5.07 disclosure presents the final voting results from Novavax's June 18, 2026 Annual Meeting of Stockholders, including election of three Class I directors, advisory approval of named executive officer compensation, amendments to two equity incentive plans, and ratification of Ernst & Young LLP as independent auditor. The filing directly matches the shareholder_vote_results event type and is material to investors as it confirms governance outcomes and shareholder approval of key compensation and equity plan matters.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 95%
filed 2026-06-23
Item 1.03
Office Properties Income Trust emerged from Chapter 11 bankruptcy reorganization under the Fourth Amended Joint Chapter 11 Plan of Reorganization filed April 21, 2026 with the U.S. Bankruptcy Court for the Southern District of Texas. The emergence resulted in cancellation of all pre-bankruptcy common shares and senior notes, termination of the DIP Credit Agreement, and a complete restructuring of the company's capital structure and ownership.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-23
Item 5.01
The company's emergence from bankruptcy resulted in a material change of control, with certain holders of Old September 2029 Senior Secured Notes and DIP Claims acquiring approximately 67% of the Reorganized Common Equity through debt-to-equity conversion. This change of control was effectuated through the bankruptcy reorganization plan and represents a fundamental shift in ownership and control of the registrant.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-23
Item 2.03
The company issued $420 million in 2029 Secured Exit Notes and $385 million in New 2027 Senior Secured Notes as part of its emergence from Chapter 11 bankruptcy reorganization, with these securities issued in exchange for allowed claims against the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 3.02
The company issued 21,953,577 shares of Reorganized Common Equity and New Warrants (exercisable for 5.0% of outstanding equity) without registration under the Securities Act in reliance on Section 1145(a) of the Bankruptcy Code to debt holders and other claimants in connection with the bankruptcy emergence.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
Five new trustees were elected effective as of the company's emergence from bankruptcy: Jonathan Heller, Jonathan Kolatch, William A. Lamkin, Adam D. Portnoy, and Irvin Schlussel. This represents a complete board reconstitution following the Chapter 11 reorganization, with the new trustees assigned to various committees and compensation arrangements.
View raw filing on EDGAR →
8-K
Governance Other
confidence 92%
filed 2026-06-23
Item 5.03
The company amended its Declaration of Trust and Bylaws to implement material governance changes, including requiring a two-thirds shareholder vote for trustee removal, adding new corporate opportunity provisions limiting fiduciary duties, granting special meeting rights to shareholders holding >50% of votes, and establishing detailed board composition rules tied to ownership thresholds for designated parties.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-06-23
Item 8.01
The company disclosed material federal income tax considerations arising from its emergence from Chapter 11 bankruptcy reorganization, including cancellation of debt income, Section 382 ownership change limitations on NOL utilization, and potential restrictions affecting REIT qualification and shareholder tax treatment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-23
Item 8.01
RMR LLC, the Company's majority-owned subsidiary, entered into amended management agreements with OPI upon OPI's emergence from Chapter 11 bankruptcy on June 17, 2026. The disclosure centers on the restructuring and renewal of material contractual relationships following OPI's reorganization, including new fee structures ($14.0 million annual business management fee, 3% property management fee, 5% construction supervision fee) and equity issuances (2% immediate, up to 8% contingent on performance metrics). While technically a contract renewal rather than a traditional M&A transaction, this represents a material restructuring of RMR's relationship with a significant client emerging from bankruptcy protection, affecting the Company's future cash flows and equity interests.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a clear disclosure of shareholder vote results from AudioEye's 2026 Annual Meeting of Stockholders held on June 22, 2026. The filing presents the final voting tallies for two proposals: election of five directors and advisory approval of named executive officer compensation. This is a quintessential Item 5.07 disclosure and is material to investors as it reflects stockholder approval of governance and compensation matters.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
Bartolomeo A. Frabotta was appointed as Chief Operating Officer of Clean Energy Fuels Corp. effective June 23, 2026, representing a material promotion from his prior role as Group Vice President of Operations. The appointment includes a detailed employment agreement with base salary of $545,056, 100% bonus eligibility, 50,000 RSU equity grants, and severance terms, and makes him a named executive officer.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-23
Item 1.01
Kimbell Royalty Partners closed a $145.9 million acquisition of mineral and royalty interests from Mesa Royalties on June 22, 2026, comprised of $44.0 million in cash and approximately 6.9 million newly issued common units, adding approximately 1,390 Boe/d of production across 16 Permian counties.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-06-23
Item 8.01
The filing discloses results of a shareholder vote held on June 17, 2026, regarding an extension of TDAC's deadline to consummate a business combination. The press release reports that 95% of shares voted were in favor of the extension and that 85% of shareholders did not redeem their shares, with $156.8mm remaining in trust. This is a direct disclosure of shareholder vote results under Item 5.07, material to investors assessing the likelihood and funding status of the proposed ProLogium merger.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
The filing discloses the election of three new directors to Bank First Corporation's Board of Directors on June 16, 2026: SriRaj Kantamneni, Tracy C. Pearson, and William J. Ring, each for three-year terms. This is a clear executive appointment event involving multiple board-level positions, which is material to investors' assessment of corporate governance and leadership composition.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-23
Item 8.01
The filing discloses the issuance of asset-backed securities (Notes) by Ford Credit Auto Owner Trust 2026-B, with the Registrant (Ford Credit Auto Receivables Two LLC) serving as the Depositor. The 8-K is filed to satisfy an undertaking to provide legality and tax opinions at the time of issuance, with counsel opinions attached as exhibits. This constitutes a material debt issuance creating a direct financial obligation.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-23
EX-99.3
Orla Mining Ltd. has entered into a court-approved plan of arrangement under the Canada Business Corporations Act whereby Equinox Gold Corp. will acquire all issued and outstanding shares of Orla Mining Ltd. in exchange for Equinox common shares (1.00 per Orla share) and US$0.0001 cash per share. The arrangement requires shareholder approval by at least 66⅔% vote at a special meeting scheduled for July 22, 2026.
View raw filing on EDGAR →
8-K
Operational Other
confidence 82%
filed 2026-06-23
Item 8.01
Verastem disclosed preliminary clinical trial data from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375, a KRAS G12D inhibitor, demonstrating clinical efficacy and favorable safety profile across multiple cancer indications (pancreatic, colorectal, lung), and announced intent to collaborate with Erasca, Inc. on a preclinical combination study. This material clinical development milestone supports advancement toward Phase 2 trials and planned Phase 3 initiation by 1H 2027, materially affecting investor assessment of the company's pipeline and competitive position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This Item 5.07 filing discloses the results of Fortress Biotech's June 17, 2026 annual meeting of stockholders, including voting outcomes for two proposals: (i) election of seven directors and (ii) ratification of KPMG LLP as independent auditor. The detailed vote tallies for each director and the auditor ratification constitute a classic shareholder_vote_results disclosure, which is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-06-23
EX-99.1
Nyxoah received $15 million (€13.8 million) from the second tranche of its European Investment Bank (EIB) loan facility, representing a drawdown of an existing debt facility. This non-dilutive debt funding complements a concurrent equity raise, bringing total June 2026 capital raised to $110 million.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-23
Item 8.01
The filing discloses the adjournment of a special stockholder meeting to vote on TWO's proposed acquisition by CrossCountry Intermediate Holdco, LLC (an affiliate of CrossCountry Mortgage, LLC). The transaction involves a $12.00 per share cash offer representing a 21% premium to unaffected share price and is described as "fully financed" with 47 of 53 regulatory approvals secured and expected to close in August 2026. This is a material acquisition event requiring stockholder approval, making it an ma_activity disclosure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
This press release announces the design and regulatory alignment of a Phase 2b clinical trial (NOV-ERA study) for ontunisertib in fibrostenosing Crohn's disease, including FDA alignment on primary endpoints, protocol submission to regulatory agencies, and expected study initiation in H2 2026. This is a material operational/clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress in late-stage development of a key product candidate, but does not fit the discrete event categories (earnings, M&A, executive changes, etc.) and is best classified as an operational milestone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 8.01
Quoin announced FDA conditional approval of the brand name QYLEKI™ for QRX003, its investigational treatment for Netherton Syndrome, representing a material regulatory milestone in the drug development pathway. The company expects to initiate a Phase 3 pivotal study in H2 2026 and anticipates filing an NDA in 2027, advancing the lead candidate toward potential commercialization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 3.02
Eagle Point Trinity Senior Secured Lending Co issued 36,782.83 common shares for $373,000 in aggregate proceeds pursuant to subscription agreements, with the offer and sale exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-23
Item 5.02
Kelly B. Rose, Senior Vice President, Legal, General Counsel and Corporate Secretary of ConocoPhillips, announced her retirement effective September 1, 2026. This is a clear departure of a named executive officer from a senior leadership position. The General Counsel role is material to investors' assessment of the company's legal and governance oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Orchestra BioMed's 2026 Annual Meeting of Stockholders held on June 23, 2026. The filing presents voting results for five proposals: election of three Class III directors (David P. Hochman, Darren R. Sherman, and Eric S. Fain), ratification of Ernst & Young LLP as independent auditor, approval of the 2026 Employee Stock Purchase Plan, advisory vote on named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed. This is a material governance event affecting investor understanding of board composition and corporate governance decisions.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-23
Item 5.02
The disclosure centers on the termination of Áine Miller, Senior Vice President and Head of Ireland Office, effective November 15, 2026, pursuant to a compromise agreement entered into on June 19, 2026 in connection with the Company's March 2026 restructuring. While the filing also mentions compensatory arrangements (RSU grant and pension contribution), the principal disclosed action is the executive's departure from the Company.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-23
EX-99.1
This exhibit is a formal Report of Voting Results filed pursuant to Section 11.3 of National Instrument 51-102, disclosing the outcomes of Eldorado Gold's Annual Shareholders Meeting held on June 23, 2026. It reports ballot results for election of nine directors, appointment of KPMG LLP as auditors, authorization of auditor remuneration, and an advisory vote on executive compensation — all standard shareholder-vote matters that materially affect governance and investor confidence in the company's leadership and oversight.
View raw filing on EDGAR →
6-K
M&A activity
confidence 85%
filed 2026-06-23
EX-99.1
ASUR's Board proposes to internalize technical assistance and technology transfer services currently outsourced to ITA through a merger of one or more entities into ASUR, subject to shareholder approval. This represents a material acquisition or change in business structure. The transaction is expected to result in issuance of approximately 7.25 million new shares and is accompanied by extraordinary dividends of Ps. 10.00 per share, indicating a significant capital event. While the language frames this as "internalization" rather than a traditional M&A transaction, the substance—bringing an outsourced business function in-house through merger and equity issuance—constitutes material acquisition activity requiring shareholder approval.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-23
EX-99.1
This news release announces the results of Eldorado Gold's 2026 Annual Meeting of Shareholders held on June 23, 2026. It discloses the election of nine directors with specific voting tallies (votes for/against each nominee), shareholder approval of independent auditors, authorization of auditor compensation, and approval of an advisory resolution on executive compensation. The disclosure of director elections and shareholder votes at an annual meeting directly matches the `shareholder_vote_results` taxonomy category, and the results are material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
The Board appointed Daniel M. Skovronsky, M.D., Ph.D., to serve as a director effective June 16, 2026, increasing the Board size from nine to ten members. The disclosure centers on the appointment of a new director with relevant scientific and pharmaceutical R&D expertise, making this a clear exec_appointment event. The appointment is material as it represents a change in the composition of the Board of Directors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-23
Item 8.01
The filing discloses the completion of all regulatory approvals for a material merger transaction. ProAssurance entered into a Merger Agreement on March 19, 2025, with The Doctors Company, whereby ProAssurance will become a wholly owned subsidiary. The disclosure confirms that as of June 23, 2026, all required regulatory approvals—including stockholder approval (June 24, 2025), FTC early termination (July 2, 2025), and all insurance regulator approvals—have been received, with closing expected on June 26, 2026. This represents a change of control and material acquisition activity requiring 8-K disclosure under Item 1.01 or 2.01.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
Ioneer announced entry into non-binding letters of intent with KIND and Hyundai Engineering to advance the Rhyolite Ridge Lithium-Boron Project toward a Final Investment Decision. While the LOIs are explicitly non-binding and create no legal obligations, they represent a material strategic partnership milestone with major Korean entities that strengthens the path to project financing and construction. This is an operational/strategic business development event that would affect a reasonable investor's assessment of project execution risk and financing prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-23
Item 7.01
Galectin announced positive feedback from an FDA Type C meeting regarding belapectin's development pathway for MASH cirrhosis, including FDA agreement on the primary endpoint (composite liver outcome including large esophageal varices), central endoscopy review methodology, and regulatory path toward full approval. This is a material regulatory milestone that clarifies the clinical development strategy and regulatory framework for the company's lead drug candidate, but does not fit the specific categories of earnings release, M&A activity, or other named event types. It is clearly operational/strategic in nature—a significant development program milestone with regulatory alignment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-23
Item 5.07
Broadway Financial Corporation held its Annual Meeting of Stockholders on June 17, 2026, with voting results on four matters: election of three directors (Brian E. Argrett, Mary Ann Donovan, Mary M. Hentges) to serve until 2029; ratification of Crowe LLP as independent auditor for fiscal 2026; advisory approval of executive compensation; and stockholder selection of annual frequency for future advisory compensation votes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a clear disclosure of shareholder voting results from EverCommerce's June 18, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports the voting outcomes for two proposals: election of three Class II Directors (Amy Guggenheim Shenkan, John Rudella, and Mark Hastings) and ratification of Ernst & Young LLP as independent auditor. All three director nominees and the auditor ratification passed with overwhelming majorities, representing a routine but material governance event that affects investor understanding of board composition and audit oversight.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-23
Item 3.01
DevvStream received a Nasdaq Hearings Panel determination to suspend its securities from Nasdaq effective June 24, 2026, due to noncompliance with the Minimum Bid Price Rule (Rule 5550(a)(2)) and failure to satisfy the Net Income Rule (Rule 5550(b)). The filing explicitly discloses the suspension decision and the Company's intent to appeal to the Listing Council, with shares expected to transfer to the Pink Limited Market and potentially OTCQB. This is a clear delisting risk event under Item 3.01.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This Item 5.07 disclosure presents the complete voting results from Genco's June 18, 2026 Annual Meeting of Shareholders, including election of six directors, advisory vote on executive compensation, approval of equity plan amendment, ratification of auditors, ratification of shareholder rights agreement, and rejection of two shareholder proposals. The detailed tabulation of votes for and against each proposal is the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-23
Item 1.01
IFF entered into a $1 billion senior unsecured delayed draw term loan facility on June 23, 2026, to refinance €800 million of Senior Notes due September 25, 2026. This represents a material creation of a new direct financial obligation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-23
Item 1.01
Sensient entered into a Credit Agreement on June 18, 2026, establishing an unsecured delayed-draw term loan facility of up to $400 million with a five-year maturity, to be used for refinancing existing indebtedness and general corporate purposes.
View raw filing on EDGAR →